Mergers & Acquisitions ·
Glucotrack, Inc. completed a strategic business combination with Lōkahi Therapeutics, Inc. on July 14, 2026
GCTKGlucotrack, Inc.
Glucotrack, Inc. completed a strategic business combination with Lōkahi Therapeutics, Inc. on July 14, 2026. Under the merger agreement, Lōkahi Therapeutics becomes the controlling business, with its securityholders expected to hold approximately 90.0% of the combined company on a fully diluted basis through a combination of common stock and Series A convertible preferred stock. Erik Emerson was appointed Chief Executive Officer, replacing Paul V. Goode, who will serve as Chief Technical Officer and CEO of the Glucotrack continuous blood glucose monitoring subsidiary. The transaction includes a planned private placement of up to $30,000,000 and a $4.45 million bridge financing. Glucotrack, Inc. is a medical technology company focused on developing continuous blood glucose monitoring systems for diabetes management.